RGEN

RepligenC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-07-18

Current thesis

The primary-source case is that Repligen entered 2026 with strong orders, then followed with an 11% organic-growth Q1, adjusted operating-margin expansion, and a higher EPS outlook, which supports a monitoring-positive view that demand in core bioprocessing tools is holding up better than feared [#SEC-8K-2026-02-24] [#SEC-8K-2026-05-05].

Posture

Mixed

Lead driver

Value

What changed

Value remains the lead driver in the composite, 7D delta -0.3.

What can break

FY26 reported revenue guidance was lowered versus the initial February range, even though organic-growth guidance was reiterated, leaving less room for top-line disappointment if orders soften [#SEC-8K-2026-02-24] [#SEC-8K-2026-05-05].

Momentum

Value

Sentiment

Setup hits (3d)

— · Net —

AI TargetsBase $145.00 · Bull $165.00 · Bear $108.00

Data freshness

Prices

As of 2026-07-18

Fundamentals

As of 2026-07-17 • Vendor: Data Vendor v1

Scores

As of 2026-07-18 • Model: HYBRID_IC_RP

AI Memo

As of 2026-06-23 • Model: RankAlpha Sentiment Codex

Investment thesis

As of 2026-07-18

Supporting evidence

What

Grade C · Mixed

Confidence Medium · Net —

Target $176.28

Why

Momentum56 · Δ7d -16.7

Value59 · Δ7d -0.3

Sentiment42 · Δ7d -5.4

So what

Balanced signals. Wait for confirmation before sizing up.

Setup hits not loaded

Load setup hits to see net bias and recent triggers.

Load setup hits

Lead driver: Value · See fundamentals

Momentum

26% active weight

Current posture

7d trendImproving

Δ7d

-16.7

Δ21d

-24.7

Value

39% active weight

Current posture

7d trendFlat

Δ7d

-0.3

Δ21d

-0.1

Sentiment

34% active weight

Current posture

7d trendSoftening

Δ7d

-5.4

Δ21d

-2.0

Why this grade

Composite grade C. Momentum 55.6 / Value 58.8 / Sentiment 41.7

Fundamentals (TTM)

As of 2026-07-17

Market Cap

$8.31B

Beta

1.13

Shares Out

56.41M

P/E (TTM)

6580.2

P/S (TTM)

13.47

P/FCF (TTM)

89.57

Rev YoY

+14.8%

EPS YoY

+42.6%

Gross Margin

+47.8%

Op Margin

+0.1%

Net Debt

-$77.68M

Current Ratio

9.20

As of 2026-07-18 • Updated nightlySource: Internal modelMethodology